JP6170675B2 - 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 - Google Patents

受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 Download PDF

Info

Publication number
JP6170675B2
JP6170675B2 JP2012551318A JP2012551318A JP6170675B2 JP 6170675 B2 JP6170675 B2 JP 6170675B2 JP 2012551318 A JP2012551318 A JP 2012551318A JP 2012551318 A JP2012551318 A JP 2012551318A JP 6170675 B2 JP6170675 B2 JP 6170675B2
Authority
JP
Japan
Prior art keywords
peptide
rap
fucosidase
complex
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012551318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518128A (ja
JP2013518128A5 (https=
Inventor
トッド シー． ザンケル，
トッド シー． ザンケル，
Original Assignee
ラプトール ファーマシューティカルズ インコーポレイテッド
ラプトール ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラプトール ファーマシューティカルズ インコーポレイテッド, ラプトール ファーマシューティカルズ インコーポレイテッド filed Critical ラプトール ファーマシューティカルズ インコーポレイテッド
Publication of JP2013518128A publication Critical patent/JP2013518128A/ja
Publication of JP2013518128A5 publication Critical patent/JP2013518128A5/ja
Application granted granted Critical
Publication of JP6170675B2 publication Critical patent/JP6170675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012551318A 2010-01-28 2011-01-28 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 Expired - Fee Related JP6170675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29917710P 2010-01-28 2010-01-28
US61/299,177 2010-01-28
PCT/US2011/022917 WO2011094536A1 (en) 2010-01-28 2011-01-28 Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016043181A Division JP2016145231A (ja) 2010-01-28 2016-03-07 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法

Publications (3)

Publication Number Publication Date
JP2013518128A JP2013518128A (ja) 2013-05-20
JP2013518128A5 JP2013518128A5 (https=) 2014-02-20
JP6170675B2 true JP6170675B2 (ja) 2017-07-26

Family

ID=44319804

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012551318A Expired - Fee Related JP6170675B2 (ja) 2010-01-28 2011-01-28 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
JP2016043181A Pending JP2016145231A (ja) 2010-01-28 2016-03-07 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016043181A Pending JP2016145231A (ja) 2010-01-28 2016-03-07 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法

Country Status (10)

Country Link
US (1) US20110189084A1 (https=)
EP (1) EP2528613B1 (https=)
JP (2) JP6170675B2 (https=)
KR (1) KR101784539B1 (https=)
CN (1) CN102905716B (https=)
AU (1) AU2011210756B2 (https=)
CA (1) CA2788175A1 (https=)
ES (1) ES2555555T3 (https=)
TW (1) TWI558397B (https=)
WO (1) WO2011094536A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
RU2474423C1 (ru) * 2011-12-20 2013-02-10 Федеральное государственное бюджетное учреждение науки Институт общей физики им. А.М. Прохорова Российской академии наук (ИОФ РАН) Способ лечения метастазов печени
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
CN107848970B (zh) * 2015-07-30 2021-07-06 地平线孤儿病有限责任公司 岩藻糖苷酶抑制剂
WO2020229968A1 (en) * 2019-05-10 2020-11-19 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US5153325A (en) 1989-06-27 1992-10-06 Monsanto Company Fucosidase inhibitor
US5100797A (en) 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5096909A (en) 1989-06-27 1992-03-17 Monsanto Company Fucosidase inhibitor
US5017704A (en) 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5240707A (en) 1990-04-12 1993-08-31 Merrell Dow Pharma Alpha-mannosidase and fucosidase inhibitors
CA2040058C (en) * 1990-04-12 2001-10-23 Robert A. Farr Alpha-mannosidase and fucosidase inhibitors
US5474766A (en) 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU1840101A (en) * 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
EP1411952B1 (en) * 2001-06-29 2009-04-22 Glykos Finland Oy Use of at least one glycoinhibitor substance against infectious diseases
US6852842B2 (en) 2002-08-26 2005-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for functional kidney imaging using small dendrimer contrast agents
CA2525236C (en) * 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CN101283046A (zh) 2005-07-18 2008-10-08 斯克里普斯研究学院 制备两亲性树枝状聚合物的方法
WO2008011617A2 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Shallow-trench-isolation (sti)-bounded single-photon avalanche photodetectors
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US20080116171A1 (en) * 2006-11-22 2008-05-22 Clarkson University Method For The Preferential Polishing Of Silicon Nitride Versus Silicon Oxide
KR20100015786A (ko) * 2007-03-21 2010-02-12 랩터 파마슈티컬 인코포레이티드 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
US8236753B2 (en) * 2007-12-10 2012-08-07 The Brigham And Women's Hospital, Inc. RAP variants for drug delivery and methods of use thereof
WO2009151687A2 (en) * 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates

Also Published As

Publication number Publication date
AU2011210756B2 (en) 2016-11-03
HK1181642A1 (zh) 2013-11-15
ES2555555T3 (es) 2016-01-04
EP2528613A4 (en) 2013-06-05
AU2011210756A1 (en) 2012-08-16
WO2011094536A1 (en) 2011-08-04
JP2013518128A (ja) 2013-05-20
CN102905716B (zh) 2016-06-01
KR20130025866A (ko) 2013-03-12
EP2528613B1 (en) 2015-10-21
CN102905716A (zh) 2013-01-30
KR101784539B1 (ko) 2017-10-11
TW201132343A (en) 2011-10-01
US20110189084A1 (en) 2011-08-04
JP2016145231A (ja) 2016-08-12
CA2788175A1 (en) 2011-08-04
EP2528613A1 (en) 2012-12-05
TWI558397B (zh) 2016-11-21

Similar Documents

Publication Publication Date Title
EP2063905B1 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
JP2010503710A5 (https=)
EP3967755B1 (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
JP2016145231A (ja) 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
JP6981961B2 (ja) フコシダーゼ阻害剤
US20140171365A1 (en) Pegylated human hdl particle and process for production thereof
US20150353930A1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
KR102387320B1 (ko) 약물 반응성 예측을 위한 대장암 진단 또는 검출용 조성물, 대장암 예방 또는 치료용 조성물
HK1181642B (en) Method for treating liver disorders with receptor associated protein ( rap) peptide-fucosidase inhibitor conjugates
EP4005583A1 (en) Cp2c-targeting peptide-based anticancer agent
US20230084893A1 (en) METHODS OF TREATING CLEAR CELL RENAL CELL CARCINOMA (ccRCC) USING AXL DECOY RECEPTORS
US20120157380A1 (en) Pegylated human apoa-1 and process for production thereof
IL323919A (en) Administration of a beta-catenin antagonist and methods of use
HK40116513A (en) Methods of treating tissue calcification
HK1132930B (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
HK40070846B (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20160422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160422

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170703

R150 Certificate of patent or registration of utility model

Ref document number: 6170675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees